Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 9/2016

01.09.2016 | Inflammatory Bowel Disease (S Hanauer, Section Editor)

Next-Generation Therapeutics for Inflammatory Bowel Disease

verfasst von: Parambir S. Dulai, William J. Sandborn

Erschienen in: Current Gastroenterology Reports | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Tumor necrosis factor (TNF) antagonists are the cornerstone of therapy for moderately to severely active inflammatory bowel disease (IBD). Although our understanding of pharmacokinetics, pharmacodynamics, and treatment optimization for these agents has evolved considerably over the past decade, a substantial majority of individuals fail to respond or lose response to TNF-antagonists over time. A need therefore remains for efficacious treatment options in these patients. Alternative immunological targets have now been identified, and several novel therapeutic agents are in development for IBD. In this review article, we discuss these novel therapeutic agents, with a particular focus on those demonstrated to be efficacious in phase 2 and 3 clinical trials. We further discuss considerations to be made when integrating these agents into routine practice over the next decade.
Literatur
1.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet (Lond Engl). 2008;371(9613):660–7.CrossRef
2.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet (Lond Engl). 2015;386(10006):1825–34.CrossRef
3.
Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63(12):1843–53.CrossRefPubMed
4.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3.CrossRefPubMed
5.
Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015;82(2):246–55.CrossRefPubMed
6.
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease—algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.CrossRefPubMed
7.
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443–51. quiz e88-9.CrossRefPubMed
8.
Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):525–41.CrossRefPubMed
9.•
Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–62. Pivotal phase 2 trial of a first in class biologic agent that modulates sphingosine-1-phospate receptors and inhibits T cell release from lymph nodes.CrossRefPubMed
10.•
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. Phase 3 trial that led to the approval of vedolizumab in ulcerative colitis.CrossRefPubMed
11.•
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. Phase 3 trial that led to the approval of vedolizumab in Crohn's disease.CrossRefPubMed
12.
Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090–102.CrossRefPubMed
13.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016.
14.
Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, et al. Vedolizumab effectiveness and safety over the first year of use in an ibd clinical practice. J Crohns Colitis. 2016;10(4):402–9.CrossRefPubMed
15.
Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–85.CrossRefPubMed
16.
Peerani F, Narula N, Dulai PS, Chaudrey K, Whitehead D, Hudesman D, et al. Sa1888 Efficacy and predictors of outcomes of vedolizumab for ulcerative colitis in clinical practice. Gastroenterology.150(4):S392-S3.
17.
Dulai PS, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, et al. Sa1889 Efficacy and predictors of outcomes of vedolizumab for Crohn’s disease in clinical practice. Gastroenterology.150(4):S393.
18.•
Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–27.e3. This study demonstrated that rates of clinical remission in Crohn’s disease with vedolizumab were significantly influenced by the duration of therapy, and this more pronounced among individuals with prior exposure to anti-TNF therapy. CrossRefPubMed
19.
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (Lond Engl). 2014;384(9940):309–18.CrossRef
20.
Reinisch W, Sandborn W, Danese S, Cataldi F, Hebuterne X, Salzberg B, et al. 901a A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT Study. Gastroenterology.148(4):S-1193.
21.
Sandborn W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, et al. 825 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease: results of the OPERA study. Gastroenterology.148(4):S-162.
22.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.CrossRefPubMed
23.
Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao L-L, et al. O-001 a multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to Anti-TFN[alpha]: UNITI-1. Inflamm Bowel Dis. 2016;22:S1.CrossRefPubMed
24.
Late-breaking abstracts. United European Gastroenterology Journal. 2015;3(6):561-71.
25.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2016;14(2):242–50. e1-2.CrossRef
26.
Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—the McGill experience. J Crohns colitis. 2014;8(11):1516–22.CrossRefPubMed
27.
Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108(4):601–9.CrossRefPubMedPubMedCentral
28.•
Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–13. Pivotal phase 2 trial of a first in class biologic anti-sense agent.CrossRefPubMed
29.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.CrossRefPubMed
30.
OP019. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. J Crohn's Colitis. 2016;10 suppl 1:S15–S.
31.
DOP071. Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of phase 3 induction studies. J Crohn's Colitis. 2016;10 suppl 1:S73–4.CrossRef
32.
OP028. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies. J Crohn's Colitis. 2016;10 suppl 1:S23–4.CrossRef
33.
Osterman MT, Roblin X, Glover SC, Navaneethan U, Popa MA, Wyant T, et al. 512 Association of vedolizumab drug concentrations at or before week 6 with remission at week 14 in moderately to severely active ulcerative colitis patients from GEMINI 1. Gastroenterology.150(4):S105.
34.
Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E. Vedolizumab and infliximab combination therapy in the treatment of Crohn’s disease. Am J Gastroenterol. 2015;110(12):1737–8.CrossRefPubMed
Metadaten
Titel
Next-Generation Therapeutics for Inflammatory Bowel Disease
verfasst von
Parambir S. Dulai
William J. Sandborn
Publikationsdatum
01.09.2016
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 9/2016
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0522-0

Weitere Artikel der Ausgabe 9/2016

Current Gastroenterology Reports 9/2016 Zur Ausgabe

Stomach and Duodenum (J Pisegna and J Benhammou, Section Editors)

Laparoscopic-Assisted Percutaneous Endoscopic Gastrostomy

Nutrition and Obesity (S McClave and J Obert, Section Editors)

The Critical Care Obesity Paradox and Implications for Nutrition Support

Inflammatory Bowel Disease (S Hanauer, Section Editor)

Approach to the Patient with Mild Crohn’s Disease: a 2016 Update

Nutrition and Obesity (S McClave, Section Editor)

Intestinal Failure: New Definition and Clinical Implications

Esophagus (JO Clarke and NK Ahuja, Section Editors)

Endoscopic Options for Gastroesophageal Reflux: Where Are We Now and What Does the Future Hold?

Large Intestine (B Cash, Section Editor)

Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise